Art. -Nr.: HY-15523

Braco-19

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.01%
CAS. Nr.: 351351-75-2
Formel: C₃₅H₄₃N₇O₂
Molecular Weight:593.76

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Braco-19 Chemical Structure

CAS. Nr.: 351351-75-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: telomerase/telomere^[1]

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	EC₅₀	113 nM Compound: 1a	Inhibition of telomerase activity from human A2780 cells Inhibition of telomerase activity from human A2780 cells	[PMID: 16420044]
A2780	IC₅₀	0.1 μM Compound: 1	Inhibition of telomerase in human A2780 cells by TRAP assay Inhibition of telomerase in human A2780 cells by TRAP assay	[PMID: 19726112]
A2780	IC₅₀	10 μM Compound: 7	Cytotoxicity against ovarian carcinoma A2780 cell lines Cytotoxicity against ovarian carcinoma A2780 cell lines	[PMID: 14521409]
A-431	IC₅₀	15.8 μM Compound: 7	Cytotoxicity against ovarian carcinoma A431 cell lines Cytotoxicity against ovarian carcinoma A431 cell lines	[PMID: 14521409]
A549	IC₅₀	0.09 μM Compound: BRACO-19	Inhibition of human telomerase in A549 cells by TRAP assay Inhibition of human telomerase in A549 cells by TRAP assay	[PMID: 19467742]
A549	IC₅₀	2.4 μM Compound: BRACO-19	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 19053833]
A549	IC₅₀	2.42 μM Compound: 1	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 17276687]
DU-145	IC₅₀	2.3 μM Compound: 1	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 17276687]
GIST882	IC₅₀	>25 μM Compound: BRACO-19	Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay	[PMID: 19469547]
HEK-293T	IC₅₀	45 nM Compound: BRACO-19	Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay	[PMID: 17954919]
HEK-293T	IC₅₀	65 nM Compound: BRACO-19	Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay	[PMID: 17954919]
HEK-293T	IC₅₀	830 nM Compound: BRACO-19	Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay	[PMID: 17954919]
HeLa	IC₅₀	5.25 μM Compound: BRACO19	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34124673]
HGC-27	IC₅₀	2.3 μM Compound: BRACO-19	Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay	[PMID: 29724653]
HGC-27	IC₅₀	2.6 μM Compound: BRACO-19	Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay	[PMID: 19469547]
HT-29	IC₅₀	2.7 μM Compound: BRACO-19	Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 19469547]
HT-29	IC₅₀	2.7 μM Compound: BRACO-19	Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29724653]
IMR-90	IC₅₀	>25 μM Compound: 1a	Cytotoxicity in human IMR90 cells by SRB assay Cytotoxicity in human IMR90 cells by SRB assay	[PMID: 16420044]
MCF7	IC₅₀	2.2 μM Compound: BRACO-19	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 19469547]
MCF7	IC₅₀	2.2 μM Compound: BRACO-19	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29724653]
MCF7	IC₅₀	2.5 μM Compound: BRACO-19	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 19053833]
MCF7	IC₅₀	2.53 μM Compound: 1	Growth inhibition of human MCF7 cells by SRB assay Growth inhibition of human MCF7 cells by SRB assay	[PMID: 17276687]
MRC5	IC₅₀	8.3 μM Compound: Braco-19	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 38971047]
MRC5	IC₅₀	8.33 μM Compound: BRACO-19	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29323491]
U2OS	IC₅₀	>40 μM Compound: BRACO19	Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 31759730]
WI-38	IC₅₀	10.7 μM Compound: BRACO-19	Cytotoxicity against human WI38 cells after 96 hrs by SRB assay Cytotoxicity against human WI38 cells after 96 hrs by SRB assay	[PMID: 19053833]

In Vitro

Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication^[2].
BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC₅₀ for BRACO-19 in UXF1138L cells is 2.5 μM, the IC₁₀₀ is 5 μM^[1].
BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses^[1].
BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells^[2].
BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HEK 293 cells
Concentration:

20 μM; 40 μM
Incubation Time:

24 hours
Result:

Displayed low cytotoxicity and decreased the eGFP fluorescence.

In Vivo

BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts^[1].
BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Established UXF1138LX Xenografts in nude mice^[1]
Dosage:

2 mg/kg
Administration:

Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments
Result:

Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.

Chemical Information

CAS. Nr. 351351-75-2
Appearance Solid
Molecular Weight 593.76
Formel C₃₅H₄₃N₇O₂
Color Brown to orange
SMILES

CN(C1=CC=C(NC2=C(C=CC(NC(CCN3CCCC3)=O)=C4)C4=NC5=CC(NC(CCN6CCCC6)=O)=CC=C52)C=C1)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All

Sort by:

Journal Impact Factor

Nat Cell Biol

Targeting specific DNA G-quadruplexes with CRISPR-guided G-quadruplex-binding proteins and ligands. [Abstract]

2024 Jul;26(7):1212-1224. PMID: 38961283
Biochim Biophys Acta Mol Basis Dis

The sonic hedgehog pathway suppresses oxidative stress and senescence in nucleus pulposus cells to alleviate intervertebral disc degeneration via GPX4. [Abstract]

2023 Nov 16;1870(2):166961. PMID: 37979732
iScience

Genomic G-quadruplex folding triggers a cytokine-mediated inflammatory feedback loop to aggravate inflammatory diseases. [Abstract]

2022 Oct 9;25(11):105312. PMID: 36304116
Microbiol Spectr

Characterization of G-Quadruplexes in Enterovirus A71 Genome and Their Interaction with G-Quadruplex Ligands. [Abstract]

2022 Apr 21;e0046022. PMID: 35446122
SLAS Discov

A high-throughput approach to evaluating NCp7 RNA binding activity for HIV-1 drug discovery. [Abstract]

2025 Aug 11:35:100260. PMID: 40803428

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (56.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6842 mL

8.4209 mL

16.8418 mL

5 mM

0.3368 mL

1.6842 mL

3.3684 mL

10 mM

0.1684 mL

0.8421 mL

1.6842 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Angelika M Burger, et al. The G-quadruplex-interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent With Telomere Targeting and Interference With Telomerase Function. Cancer Res. 2005 Feb 15;65(4):1489-96. [Content Brief]

[2]. Prativa Majee, et al. Genome-wide Analysis Reveals a Regulatory Role for G-quadruplexes During Adenovirus Multiplication. Virus Res. . 2020 Jul [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6842 mL	8.4209 mL	16.8418 mL	42.1046 mL
	5 mM	0.3368 mL	1.6842 mL	3.3684 mL	8.4209 mL
	10 mM	0.1684 mL	0.8421 mL	1.6842 mL	4.2105 mL
	15 mM	0.1123 mL	0.5614 mL	1.1228 mL	2.8070 mL
	20 mM	0.0842 mL	0.4210 mL	0.8421 mL	2.1052 mL
	25 mM	0.0674 mL	0.3368 mL	0.6737 mL	1.6842 mL
	30 mM	0.0561 mL	0.2807 mL	0.5614 mL	1.4035 mL
	40 mM	0.0421 mL	0.2105 mL	0.4210 mL	1.0526 mL
	50 mM	0.0337 mL	0.1684 mL	0.3368 mL	0.8421 mL

Keywords

Braco-19

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Braco-19

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Braco-19

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Braco-19

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Braco-19

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Braco-19 Related Classifications

Art. -Nr.: HY-15523